University of Illinois at Chicago
Exemption #JDR439
Announcement of an Exempt Purchase
Award Info Published Thursday February 13, 2025
Optum Frontier Therapies LLCFlint, MI
- Amount: An estimated $249,000
- Terms: An estimated start date of 2/12/2025 through 6/30/2025
- Renewals: None
Summary
Vendors
1 total
0 BEP vendors
0 VBP vendors
0 Small businesses
The University award process may be delayed as this award goes through a state approval process.
First published Thursday, February 13, 2025
The University awarded a contract for Adstiladrin.
Adstiladrin is a gene therapy medication for bladder cancer treatment .
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical at a university-operated health care center or dispensary that provides care, treatment, and medications for students, faculty and staff (30 ILCS 500 / 1-13(b-5)) This gene therapy medication is necessary to provide treatment to UI Health bladder cancer patients. Without access to these type of gene therapy medications, the Hospital would not be able to offer proper patient care and would drive patients elsewhere and result in a loss of revenue to the Hospital.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire qualified veterans, minorities, females, persons with disabilities and ex-offenders.